ACTC Advanced Cell Technology Inc Advances on positive results

ACTC.OB a penny stock featured on this blog last year made some big advances Monday Jan 23, 2012, after preliminary findings of a study using Embryonic stem cells for the treatment of macular eye degeneration showed some positive findings.

The medical article is linked here (pdf) (fair use)

The excerpts from the discussion are:

We provide clinical evidence suggesting that
hESC-derived cells might be safely transplanted into
human patients (panel). In our study, we transplanted a
low dose (5×10⁴ cells) of RPE cells generated from hESCs
into one eye of two patients with different forms of
macular degeneration.

Our study is designed to test the safety and tolerability of hESC-RPE in patients with advanced-stage Stargardt’s macular dystrophy and dry age-related macular degeneration.

So far, the cells seem to have transplanted into both patients without abnormal proliferation, teratoma formation, graft rejection, or other untoward pathological reactions or safety signals. Continued follow-up and further study is needed. The ultimate therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.

and the NY times article is available here.

Excerpts:
Both patients, who were legally blind, told researchers that they had gains in eyesight that were meaningful for them. One said she could see colors better and was able to thread a needle and sew a button for the first time in years. The other said she was able to navigate a shopping mall by herself.Still, it is hard to judge much from only two patients, especially when there was no control group given a placebo treatment.Indeed, Dr. Schwartz said that the improvement in vision of the woman who could go to the mall might have been a placebo effect, though he thought the improvement in the other patient did result from the implanted cells.Yet another reason to be cautious is that Advanced Cell Technology has had a reputation for publicizing its positive work, in part because it has often been on the brink of insolvency.

So, the key thing to keep in mind is that this is still a speculative stock, so be careful but be willing to take risks - like we did a year ago :)

ACTC Announces Phase 1/2 Clinical Trial Site

Advanced Cell Technologies (a STEM cell research company) ACTC.OB announced in a press release about the selection of site for clinical trials Phase 1/2 for its macular degeneration (treatment) product.
Sentiment: Positive
More details

From Yahoo Finance:

Press Release Source: Advanced Cell Technology, Inc. On Monday May 16, 2011, 8:30 am

MARLBOROUGH, Mass., May 16, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) in Portland, Ore., has received institutional review board (IRB) approval to be a site for its Phase 1/2 human clinical trial for Stargardt's Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The Phase 1/2 trial will be prospective, open-label study designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation into patients with SMD.
"We are pleased that OHSU's Casey Eye Institute has agreed to participate as a site for this study that should help us better understand the role that RPE cells can play in the treatment of SMD," said Gary Rabin, interim chairman and CEO of ACT.  "This agreement marks another milestone in our history of successful collaboration with CEI on our RPE program.  The promising data from the collaboration, begun in 2007, helped pave the way for this trial, and we look forward to starting it in the coming weeks."
"We are honored to have been designated as a site for this groundbreaking clinical trial," said
Peter J. Francis, M.D., Ph.D., Associate Professor of Ophthalmology and Co-Director of the Oregon Retinal Degeneration Center at the Casey Eye Institute. "Our prior collaborative projects with ACT on its RPE program have generated promising results, and we are pleased to be a part of this trial for an exciting potential new treatment for SMD, using hESC-derived RPE cells."
Additional details on this study, for which the Jules Stein Institute at the University of California, Los Angeles has also received IRB approval, can be found on http://clinicaltrials.gov/; ClinicalTrials.gov Identifier: NCT01345006.